###begin article-title 0
###xml 44 50 <span type="species:ncbi:10090">Murine</span>
Macrophages Inhibit Neovascularization in a Murine Model of Age-Related Macular Degeneration
###end article-title 0
###begin article-title 1
Is IL-10 a Good Target to Inhibit Choroidal Neovascularisation in Age-Related Macular Disease?
###end article-title 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 76 82 <span type="species:ncbi:9606">people</span>
###xml 160 163 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 243 246 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 y of age in at least three continents. Choroidal neovascularization (CNV) is the process by which abnormal blood vessels develop underneath the retina. CNV develops in 10% of patients with AMD but accounts for up to 90% of the blindness from AMD.
###end p 3
###begin p 4
###xml 33 36 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 380 383 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Although the precise etiology of CNV in AMD remains unknown, the macrophage component of the inflammatory response, which has been shown to promote tumor growth and support atherosclerotic plaque formation, is thought to stimulate aberrant angiogenesis in blinding eye diseases. The current theory is that macrophage infiltration promotes the development of neovascularization in CNV.
###end p 4
###begin title 5
Methods and Findings
###end title 5
###begin p 6
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 66 69 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
###xml 56 59 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 169 172 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 368 371 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
We examined the role of macrophages in a mouse model of CNV. IL-10-/- mice, which have increased inflammation in response to diverse stimuli, have significantly reduced CNV with increased macrophage infiltrates compared to wild type. Prevention of macrophage entry into the eye promoted neovascularization while direct injection of macrophages significantly inhibited CNV. Inhibition by macrophages was mediated by the TNF family death molecule Fas ligand (CD95-ligand).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 267 270 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Immune vascular interactions can be highly complex. Normal macrophage function is critical in controlling pathologic neovascularization in the eye. IL-10 regulates macrophage activity in the eye and is an attractive therapeutic target in order to suppress or inhibit CNV in AMD that can otherwise lead to blindness.
###end p 8
###begin p 9
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
Apte and colleagues examined the role of macrophages in a mouse model of choroidal neovascularization, and showed that normal macrophage function is critical in controlling pathologic neovascularization in the eye.
###end p 9
###begin title 10
Editors' Summary
###end title 10
###begin title 11

###end title 11
###begin title 12
Background.
###end title 12
###begin p 13
###xml 867 872 <span type="species:ncbi:10090">mouse</span>
The most common cause of poor eyesight in later life in the developed world is known as age-related macular degeneration (AMD). The macula is the central part of the retina (the film-like membrane at the back of the eye), which is the most sensitive and important for sharp central vision. There are two types of advanced AMD: so-called wet, or neovascular, AMD (neovascular means "new vessel") and dry, or geographic atrophy, AMD (atrophy means "to waste away"). Wet AMD occurs when abnormal, fragile new blood vessels grow under the macula behind the retina. These blood vessels often leak blood and fluid, which lift the macula. Dry AMD occurs as the light-sensitive cells in the macula (the rods and cones) break down. To study this disease further, researchers use animal models. One such animal model is made by using a laser to damage the back of the eye in a mouse, which causes the formation of new vessels. Various treatments can then be tested to see if they have any effect on the damage.
###end p 13
###begin title 14
Why Was This Study Done?
###end title 14
###begin p 15
One theory about AMD is that the immune system may be involved in determining how severe the damage at the back of the eye is, and how much new vessel formation occurs. The researchers wanted to look at the effect of the immune system on AMD, in particular, the effect of one type of cell called a macrophage, and a substance, IL-10, that is secreted from bone marrow cells and that affects how these macrophages work.
###end p 15
###begin title 16
What Did the Researchers Do and Find?
###end title 16
###begin p 17
###xml 23 28 <span type="species:ncbi:10090">mouse</span>
###xml 211 215 <span type="species:ncbi:10090">mice</span>
###xml 323 327 <span type="species:ncbi:10090">mice</span>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
The researchers used a mouse strain in which IL-10 was absent, induced damage in the eyes that mimicked AMD, and then looked at what role macrophages had in the eye abnormalities. They found that in the eyes of mice that lacked IL-10, there was reduced new vessel formation and increased numbers of macrophages compared to mice that had normal amounts of IL-10. Also, preventing macrophages from getting into the eyes of such mice by injecting IL-10 into the eyes made the new vessel formation worse, while direct injection of macrophages made it better.
###end p 17
###begin title 18
What Do These Findings Mean?
###end title 18
###begin p 19
###xml 62 68 <span type="species:ncbi:9606">humans</span>
Although animal models cannot completely replicate disease in humans, they can give us an idea of how diseases might come about and suggest possible treatment strategies. It is possible that inhibiting the effect of IL-10, or other strategies that make macrophages more efficient in the eye, may be a useful treatment for AMD. In a related Perspective (DOI: ), Susan Lightman and Virginia Calder discuss the findings further, including suggesting new experiments that will need to be done as a next step.
###end p 19
###begin title 20
Additional Information.
###end title 20
###begin p 21
Please access these Web sites via the online version of this summary at .
###end p 21
###begin p 22
MedlinePlus encyclopedia entry on
###end p 22
###begin p 23
National Institutes of Health Senior Health page of information on
###end p 23
###begin p 24
National Eye Institute
###end p 24
###begin title 25
Introduction
###end title 25
###begin p 26
###xml 711 712 711 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b001">1</xref>
###xml 713 714 713 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b002">2</xref>
###xml 964 965 964 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b003">3</xref>
Inflammation in response to insult and injury can stimulate immunity and promote healing. However, recent work has focused on the role of chronic inflammation in the development of pathologic processes such as cancer, heart disease, and eye disorders. The macrophage component of inflammation has received attention because of macrophage production of proangiogenic and proinflammatory molecules that can fuel disease progression. In cancer, chronic inflammation has been demonstrated within tumor foci, and a number of studies suggest that tumor-associated macrophages promote the growth, proliferation, and metastasis of neoplastic cells as well as stimulate neovascularization, leading to tumor progression [1,2]. Recent research in heart disease has shown that inflammation plays a key role in atherosclerosis. Immune cells have been shown to dominate early atherosclerotic lesions, and molecules produced by these cells accelerate progression of the disease [3].
###end p 26
###begin p 27
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b004">4</xref>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b005">5</xref>
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b006">6</xref>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b007">7</xref>
###xml 423 424 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b008">8</xref>
###xml 992 993 992 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b004">4</xref>
###xml 994 995 994 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b005">5</xref>
###xml 1141 1142 1141 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b009">9</xref>
###xml 1143 1145 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b012">12</xref>
###xml 1224 1226 1224 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b010">10</xref>
###xml 287 293 <span type="species:ncbi:9606">people</span>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
###xml 673 676 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 872 877 <span type="species:ncbi:10090">mouse</span>
###xml 1122 1130 <span type="species:ncbi:9606">patients</span>
###xml 1289 1292 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Recent studies of the blinding eye disorder age-related macular degeneration (AMD) also suggest a role for inflammation, specifically macrophages, in promoting this disease [4,5]. AMD is a progressive disease that causes irreversible visual impairment and blindness in nearly 50 million people globally [6,7]. Current estimates of patients affected with AMD are higher than those of patients affected by Alzheimer disease [8]. Although both geographic atrophy and neovascularization represent advanced forms of AMD, neovascular AMD is the more aggressive form and accounts for almost 90% of blindness from this disease. It is characterized by choroidal neovascularization (CNV), which is the development of abnormal blood vessels underneath the retina. Evidence for a disease-promoting role for macrophages in neovascular AMD derives from two sources. First, studies in a mouse model showed that systemic depletion of macrophages using clodronate-filled liposomes blocked neovascularization [4,5]. Second, certain single nucleotide polymorphisms in complement factor H are observed in a significantly higher percentage of patients with AMD [9-12]. These data, along with the discovery of complement factor H in AMD lesions [10], have been interpreted to suggest that inflammation promotes CNV.
###end p 27
###begin p 28
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b013">13</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b014">14</xref>
###xml 70 74 <span type="species:ncbi:10090">Mice</span>
###xml 142 145 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 255 258 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Other recent studies suggest that macrophages may be anti-angiogenic. Mice lacking a macrophage recruitment chemokine (ccl-2) had spontaneous CNV [13], suggesting that when macrophages could not be recruited to the eye, animals were more prone to develop CNV. Another study showed that macrophages are essential to the regression of abnormal vasculature in the anterior segment of the eye [14]. Thus, the role of macrophages in pathogenic neovascularization still remains controversial.
###end p 28
###begin p 29
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b015">15</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b016">16</xref>
###xml 463 464 463 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b004">4</xref>
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b005">5</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b017">17</xref>
###xml 470 472 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b018">18</xref>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b015">15</xref>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b019">19</xref>
###xml 1123 1125 1123 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b016">16</xref>
###xml 1126 1128 1126 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b020">20</xref>
###xml 1230 1232 1230 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b021">21</xref>
###xml 1422 1424 1422 1424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b022">22</xref>
###xml 93 98 <span type="species:ncbi:10090">mouse</span>
###xml 119 125 <span type="species:ncbi:10090">murine</span>
###xml 421 424 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 521 524 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 704 707 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 727 732 <span type="species:ncbi:9606">human</span>
###xml 755 758 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1007 1012 <span type="species:ncbi:9606">human</span>
###xml 1111 1114 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1150 1155 <span type="species:ncbi:10090">mouse</span>
###xml 1225 1228 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1305 1327 <span type="species:ncbi:272636">adeno-associated virus</span>
###xml 1394 1402 <span type="species:ncbi:9606">patients</span>
###xml 1408 1411 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1586 1589 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1710 1713 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1856 1861 <span type="species:ncbi:10090">mouse</span>
###xml 2194 2199 <span type="species:ncbi:9606">human</span>
###xml 2273 2276 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Our study was designed to directly examine the complex role of macrophages in an established mouse model. Although the murine laser model is only a surrogate acute injury model for AMD-which is a chronic disease-it has been remarkably successful in predicting therapies that have since proven to be efficacious in the treatment of AMD [15,16]. It has been also been extremely accurate in revealing the pathophysiology of CNV, the sine qua non of neovascular AMD [4,5,17,18]. Photodynamic therapy, the first treatment for CNV in AMD approved by regulatory agencies in the United States, Europe, Australia, and Japan, was initially examined and proven to be efficacious in an animal model of laser-induced CNV [15,19]. The first human anti-VEGF therapy for CNV in AMD was approved by the United States Food and Drug Administration in 2005. The efficacy of anti-VEGF therapy in ocular neovascularization was initially studied in an animal laser model and was then tested in two large, randomized double-masked human clinical trials that led to the US Food and Drug Administration approval of anti-VEGF therapy for CNV in AMD [16,20]. In a laser-induced mouse model, pigment-epithelium-derived factor was demonstrated to inhibit CNV [21]. The same team of investigators has since completed a phase I trial of adeno-associated virus- pigment-epithelium-derived factor administered intravitreally in patients with CNV from AMD [22]. A preponderance of evidence in the peer-reviewed literature demonstrates that the laser model is a reliable surrogate for understanding the pathophysiology of CNV in AMD. In addition, it has proven to be an excellent model for testing molecules and compounds that successfully treat CNV. The injury to the retinal pigment epithelium (RPE) in AMD is a chronic phenomenon; nevertheless, the laser-mediated injury to the RPE in the mouse model, although acute, might simulate an accelerated phenotype of the chronic disease process. In this paper, we examine the role of innate immunity, specifically macrophage-mediated immunity, in regulating angiogenesis in the eye. We investigate the complex role of macrophages in regulating angiogenesis in an animal model of the human disease AMD and attempt to understand the pathophysiologic mechanisms of CNV that lead to blindness in AMD.
###end p 29
###begin title 30
Methods
###end title 30
###begin title 31
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse Strains
###end title 31
###begin p 32
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 22 25 22 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gld,</italic>
###xml 42 45 42 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</italic>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 130 135 <span type="species:ncbi:10090">mouse</span>
###xml 162 166 <span type="species:ncbi:10090">mice</span>
C57/BL6 (B6), B6-IL-10-/-, B6-gld, and B6-lpr mice were purchased from Jackson Laboratory (Bar Harbor, Maine, United States). All mouse experiments contained 3-5 mice and were repeated at least three times with similar results. All work was carried out in accordance with Association for Research in Vision and Ophthalmology guidelines ().
###end p 32
###begin title 33
###xml 14 20 <span type="species:ncbi:10090">Murine</span>
###xml 30 33 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Laser-Induced Murine Model of CNV
###end title 33
###begin p 34
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b017">17</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b018">18</xref>
###xml 1240 1241 1239 1240 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1377 1378 1374 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1433 1434 1430 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b004">4</xref>
###xml 1435 1437 1432 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b018">18</xref>
###xml 0 3 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 749 755 <span type="species:ncbi:9913">bovine</span>
###xml 835 840 <span type="species:ncbi:10090">mouse</span>
###xml 897 903 <span type="species:ncbi:9913">bovine</span>
###xml 919 922 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1228 1231 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1263 1266 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1420 1423 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1440 1443 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1624 1627 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
CNV was induced by rupture of the RPE and underlying Bruch's membrane with a krypton laser in 5- to 7-wk-old mice as described [17,18]. Briefly, four laser spots were placed in each fundus in the peripapillary area using a Krypton Red Laser (614 nm, 50 mum, 0.05 s, 200 mW). After 7 d, the animals were perfused with 3% FITC-conjugated high-molecular-weight dextran (2,000 kDa). A dissecting microscope was used to remove the cornea and lens and gently separate the retina from the underlying choroid and sclera. Microscissors were used to make four radial incisions in the sclero-choroidal eyecup in order to prepare choroidal flat mounts on glass slides. The tissues were incubated in 4% paraformaldehyde for 45 min and washed three times with 3% bovine serum albumin. The tissues were then counter-stained with Cy-3-conjugated anti-mouse elastin antibody for 1 h and washed three times with 3% bovine serum albumin. CNV was identified as FITC-perfused vessels above the plane of Bruch's membrane on confocal microscopy. Images were captured in a three-dimensional stacked fashion for volumetric analysis by Metamorph imaging software (Universal Imaging, Sunnyvale, California, United States). Data were recorded as volume of CNV (microns3) +/- standard error. CNV volumes for all eyes in a treatment group were averaged and compared individually to controls using Student's t test, which has been utilized in similar CNV studies [4,18]. CNV grading was performed in a masked manner, where the individual groups were coded with letters and then presented to the grader for confocal microscopy and quantitative analysis of CNV.
###end p 34
###begin title 35
Cytokine and Antibody Injections
###end title 35
###begin p 36
###xml 285 287 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b023">23</xref>
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
###xml 9 14 <span type="species:ncbi:10090">mouse</span>
###xml 168 172 <span type="species:ncbi:10090">Mice</span>
###xml 416 419 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 433 438 <span type="species:ncbi:10090">mouse</span>
###xml 585 590 <span type="species:ncbi:10090">mouse</span>
Rat anti-mouse monoclonal antibodies to IL-10 (JES5.2A5) and an isotype-matched (IgG2b) antibody were purchased from Genzyme (Cambridge, Massachusetts, United States). Mice received intravenous injections (500 mug) 1 d prior to laser photocoagulation (day -1) as described previously [23]. Antibody injections were repeated on day 0 (day of laser) and day 1, prior to harvesting of the eyes on day 7 for analysis of CNV. Recombinant mouse IL-10 was purchased from BD Biosciences (San Jose, California, United States). Five microliters (100 ng) was injected into the vitreous cavity of mouse eyes with a 33-gauge needle fitted to a Hamilton syringe on day 0 or 3 after laser treatment. Anti-CD11b (5C6), anti-F4/80 (C1;A3-1), and the isotype control (IgG2b) were purchased from Serotec (Raleigh, North Carolina, United States). We injected 500 mug of each antibody on days -1, 0, and 1. Biotinylated anti-Fas ligand (FasL) (MFL-3) and Strepavidin-FITC for flow cytometry were purchased from BD Biosciences.
###end p 36
###begin title 37
Immunohistochemistry
###end title 37
###begin p 38
###xml 342 343 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Sclero-choroidal flat mounts were prepared 7 d after laser treatment. PE-conjugated anti-CD11b antibody (1:100) or isotype-matched control antibody (BD Biosciences) was used to stain the mounts for 1 h at room temperature; the mounts were then washed with PBS three times and analyzed by 3-D confocal microscopy. Numbers of macrophages (CD11b+) were counted per lesion (per 20x field centered on the laser lesion), and average numbers were represented. Lesions in flat mounts were also analyzed for neutrophils with PE-conjugated anti-Gr-1 antibody, for dendritic cells with PE-conjugated anti-CD11c, and for T cells with PE-conjugated CD3 antibody (BD Biosciences). PE-conjugated F4/80 antibody (Caltag Laboratories, Burlingame, California, United States) was also used to stain macrophages. PE-conjugated anti-IL-10 antibody (1:100) and isotype control were purchased commercially (BD Biosciences) and used for staining paraffin-sectioned eyes as described above.
###end p 38
###begin title 39
Bone Marrow Culture
###end title 39
###begin p 40
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b024">24</xref>
###xml 455 456 455 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 807 808 807 808 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Cells for intravitreal injections were prepared from bone marrow culture and spleen. Bone marrow was isolated from proximal limb bones as described previously [24]. Briefly, all muscle tissue was removed from the bones and the bones were washed in 70% alcohol for 5 s prior to two washes in PBS. The ends of the bones were cut with scissors and the marrow harvested by using a syringe and 25-gauge needle to flush the bones with complete RPMI. Then 2 x 106 cells were cultured for 10 d in 10 ml of complete RPMI and 1,000 U/ml GM-CSF in 100-mm petri dishes. On day 3 and 6, an additional 500 U/ml and 1,000 U/ml GM-CSF were added, respectively. On day 10, the non-adherent cells containing dendritic cells were discarded. The adherent cells were mechanically removed and harvested with a cell scraper. CD11b+ cells were then isolated by positive selection (see below).
###end p 40
###begin title 41
Positive Selection Using Spleen Cells
###end title 41
###begin p 42
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 16 17 16 17 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 186 187 186 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 204 205 204 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 61 66 <span type="species:ncbi:10090">mouse</span>
###xml 371 375 <span type="species:ncbi:10090">mice</span>
###xml 453 457 <span type="species:ncbi:10090">mice</span>
CD11b+ and F4/80+ macrophages were purified from dissociated mouse spleen cells or GM-CSF-cultured macrophages using the PE-positive selection kit (SpinSep, StemCell Technologies, ). CD3+ T cells or CD11c+ dendritic cells were also isolated by the same protocol. Cell purity was greater than 90% by flow cytometry. Cells were injected into the vitreous cavity of eyes of mice using a 33-gauge Hamilton needle on the same day as laser treatment. Control mice were injected with PBS.
###end p 42
###begin title 43
###xml 11 15 <span type="species:ncbi:10090">Mice</span>
Transgenic Mice
###end title 43
###begin p 44
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VMD2-IL-10</italic>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b025">25</xref>
###xml 164 175 164 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pVMD2-placF</italic>
###xml 252 256 252 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VMD2</italic>
###xml 395 400 395 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 417 427 417 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VMD2-FN-14</italic>
###xml 454 459 454 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FN-14</italic>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b026">26</xref>
###xml 752 757 752 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 361 364 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 535 540 <span type="species:ncbi:10090">mouse</span>
###xml 978 982 <span type="species:ncbi:10090">mice</span>
VMD2-IL-10 transgenic (Tg) mice were constructed to overexpress IL-10 in RPE cells. VMD2 (Bestrophin) localizes to the basolateral plasma membrane of the RPE [25] (pVMD2-placF was provided by Noriko Ezumi, Johns Hopkins Medical School). We removed the VMD2 promoter and cloned it into the pCI plasmid (Promega, Madison, Wisconsin, United States), replacing the CMV promoter, and then placed the IL-10 ORF downstream. VMD2-FN-14 was made by replacing the IL-10 ORF with the FN-14 ORF [26]. Tg mice were produced by injecting fertilized mouse oocytes with transgene DNA by standard protocols in the Washington University Department of Ophthalmology and Visual Science Molecular Biology Core facility. Founders were screened by PCR and used for breeding. IL-10 expression was verified by RT-PCR and immunohistochemistry. Biomicroscopic examination of the anterior and posterior segments of the eye and histopathologic analysis of ocular tissues showed no overt abnormalities. Such mice are viable and have shown normal life spans compared to littermate controls (data not shown).
###end p 44
###begin title 45
Macrophage Activation and Apoptosis Assay
###end title 45
###begin p 46
###xml 99 100 99 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 232 233 225 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 282 283 275 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 303 304 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 769 770 762 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Purified CD11b-F4/80 macrophages were placed into 96-well flat-bottom tissue culture plates (1 x 105 per well). Cells were treated with lipopolysaccharide (LPS) (0.1 mug/ml) or necrotic retinal cells for 3 h at 37 degreesC and 5% CO2 in complete RPMI. L1210-Fas target cells (2 x 104 cells labeled with 3H-thymidine) were added and the plates incubated for an additional 16-20 h. Cells were harvested by filtration through glass fiber filters (Packard Instruments, Meriden, Connecticut, United States) using a Filtermate 96-cell harvester (Packard Instruments) and counted on a microplate scintillation counter (Packard Instruments). Data were expressed as percent cell death, calculated as 100 x (counts per minute from L1210-Fas alone - counts per minute of L1210-Fas+ macrophages)/counts per minute from L1210-Fas alone.
###end p 46
###begin title 47
Preparation of Necrotic Retinal Cells
###end title 47
###begin p 48
###xml 369 370 369 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 557 558 557 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 564 565 564 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
Necrotic retinal cells were prepared from B6 mice. Eyes were removed from euthanized mice and dissected in RPMI complete medium. Anterior segment and lens were removed and discarded. The neurosensory retina was gently peeled from the choroid with fine-tip forceps and ground between two glass slides. Cells in each retina were counted and cell number adjusted to 5 x 107 per microliter. The retina was placed in RPMI complete medium and subjected to four freeze/thaw cycles using liquid nitrogen. Ten microliters of this material was added per well of CD11b+-F4/80+ macrophages.
###end p 48
###begin title 49
Statistics
###end title 49
###begin p 50
###xml 10 11 10 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b017">17</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b018">18</xref>
###xml 236 238 236 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
###xml 282 284 282 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
Student's t test was used to perform statistics on all experiments in the study, as described previously [17,18]. Individual numeric values were imported into the statistical package (SigmaPlot for Windows, 2002 version) to compute the p-value in order to determine significance. A p-value of less than 0.05 was considered to be significant.
###end p 50
###begin title 51
Results
###end title 51
###begin title 52
###xml 15 18 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
IL-10 Promotes CNV
###end title 52
###begin p 53
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b017">17</xref>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b018">18</xref>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b016">16</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b027">27</xref>
###xml 0 3 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
###xml 322 325 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 426 431 <span type="species:ncbi:9606">human</span>
###xml 445 450 <span type="species:ncbi:10090">mouse</span>
CNV in the mouse model is induced by disruption of the RPE and underlying Bruch's membrane with a krypton laser [17,18]. Following laser treatment of the eye, blood vessels penetrate the subretinal space, forming neovascular complexes. The volume of these complexes is indicative of the extent of new vessel growth (i.e., CNV). Values are easily compared among groups in the same experiment. Although only a surrogate for the human disease, the mouse model has been used extensively to study the pathogenesis of experimental neovascularization. The model has also been used in preclinical trials for testing potential therapies for AMD that have since proven effective in preventing vision loss [16,27].
###end p 53
###begin p 54
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 79 82 79 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b023">23</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b028">28</xref>
###xml 570 575 570 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 575 578 575 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 641 646 641 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 646 649 646 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 793 801 793 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g001">Figure 1</xref>
###xml 887 895 887 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g001">Figure 1</xref>
###xml 957 962 957 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 1007 1015 1007 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g001">Figure 1</xref>
###xml 1025 1030 1025 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 1030 1033 1030 1033 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1039 1047 1039 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g001">Figure 1</xref>
###xml 1140 1142 1140 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b028">28</xref>
###xml 1251 1260 1251 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030310-sg001">Figure S1</xref>
###xml 67 70 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
###xml 563 566 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 579 583 <span type="species:ncbi:10090">mice</span>
###xml 650 654 <span type="species:ncbi:10090">mice</span>
###xml 677 681 <span type="species:ncbi:10090">mice</span>
###xml 727 731 <span type="species:ncbi:10090">mice</span>
###xml 847 851 <span type="species:ncbi:10090">mice</span>
###xml 882 885 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1079 1082 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
We explored the role of inflammation by examining the induction of CNV in IL-10-/- mice. IL-10 is an anti-inflammatory cytokine that inhibits T cell and macrophage functions. It is a potent inhibitor of cytokine and chemokine production, including a number of molecules known to attract monocytes and macrophages to sites of inflammation. The absence of IL-10 typically results in substantial increases in inflammation at multiple sites following diverse stimuli [23,28]. If the current hypothesis is correct, we would expect increased inflammation and increased CNV in IL-10-/- mice. In comparing the volume of the neovascular complexes in IL-10-/- mice and-wild type (wt) B6 mice 7 d following laser treatment, we found that mice lacking IL-10 had significantly decreased new vessel growth (Figure 1A). Systemic neutralization of IL-10 in wt B6 mice also significantly diminished CNV (Figure 1B), recapitulating the effect of the targeted deletion of the IL-10 gene. Representative lesions from a B6 eye (Figure 1C) and an IL-10-/- eye (Figure 1D) show profound differences in CNV. Since IL-10 is made exclusively by hematopoietic cells [28], it is not surprising that bone-marrow-derived cells were identified as the source of IL-10 in this model (Figure S1).
###end p 54
###begin title 55
IL-10 Inhibits Recruitment of Macrophages to Neovascular Complexes
###end title 55
###begin p 56
###xml 495 500 495 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 500 503 500 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 675 683 675 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g002">Figure 2</xref>
###xml 687 692 687 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 692 695 692 695 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 702 710 702 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g002">Figure 2</xref>
###xml 774 782 774 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g002">Figure 2</xref>
###xml 818 819 818 819 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 829 834 829 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 834 837 834 837 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 934 935 934 935 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1069 1077 1069 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g002">Figure 2</xref>
###xml 1123 1124 1123 1124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1288 1296 1288 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g002">Figure 2</xref>
###xml 1594 1595 1594 1595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1601 1602 1601 1602 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1698 1699 1698 1699 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1705 1706 1705 1706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 504 508 <span type="species:ncbi:10090">mice</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
###xml 669 673 <span type="species:ncbi:10090">mice</span>
###xml 696 700 <span type="species:ncbi:10090">mice</span>
###xml 721 725 <span type="species:ncbi:10090">mice</span>
###xml 838 842 <span type="species:ncbi:10090">mice</span>
###xml 850 854 <span type="species:ncbi:10090">mice</span>
###xml 945 948 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1519 1522 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1530 1534 <span type="species:ncbi:10090">mice</span>
###xml 1555 1558 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
The effects of IL-10 in this system could be direct, where IL-10 influences endothelial cell function, or they could be the result of the hyperinflammatory response that is characteristic of IL-10-deficient animals. We have been unable to show an effect of IL-10 on vascular endothelial cell proliferation or tube formation in vitro (data not shown), and we have been unsuccessful in identifying IL-10 receptors on vascular endothelial cells. Consequently, we tested whether our observations in IL-10-/- mice and wt mice receiving anti-IL-10 were related to the increased inflammatory phenotype observed in these animals. Examination of the neovascular complexes in wt mice (Figure 2A), IL-10-/- mice (Figure 2B), and wt mice that were treated with neutralizing anti-IL-10 (Figure 2C) revealed significantly more CD11b+ cells in IL-10-/- mice and wt mice treated with neutralizing anti-IL-10 than in wt controls. Quantitation of CD11b+ cells in CNV lesions on day 7 confirmed that there are substantial increases in the number of these cells when IL-10 is not present (Figure 2D). Immunohistochemical stains for other CD11b+ cells such as dendritic cells (CD11c) and neutrophils (Gr-1) were negative, as were stains for T cells (CD3) (data not shown). Immunostaining for CD11b and F4/80 (Figure 2E) confirmed that these infiltrating cells were macrophages. While these data are consistent with the hyperinflammatory state observed in the absence of IL-10, they are not consistent with the idea that macrophages promote CNV. Since mice with low amounts of CNV had increased infiltration of CD11b+-F4/80+ inflammatory cells and a paucity of other immune cells, a more likely explanation is that CD11b+-F4/80+ macrophages are either inhibiting blood vessel formation in the retina or promoting vascular endothelial cell death.
###end p 56
###begin title 57
###xml 43 46 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Inhibiting Macrophage Recruitment Promotes CNV
###end title 57
###begin p 58
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b029">29</xref>
###xml 192 200 192 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g003">Figure 3</xref>
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 396 400 <span type="species:ncbi:10090">mice</span>
We directly tested this idea with three types of experiments. First, we used systemic injection of anti-CD11b or anti-F4/80, treatments known to prevent entry of macrophages into tissue [29]. Figure 3A shows that depletion of CD11b+ cells with anti-CD11b as well as depletion of macrophages with anti-F4/80 led to significantly increased neovascularization. Examination of the lesions in treated mice revealed that both treatments abolished the migration of macrophages into the laser lesions (data not shown). This finding further substantiates that the presence of macrophages inhibits angiogenesis in the retina.
###end p 58
###begin p 59
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 120 123 120 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 224 232 224 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g003">Figure 3</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b023">23</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b028">28</xref>
###xml 41 44 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 124 128 <span type="species:ncbi:10090">mice</span>
###xml 468 471 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Next, the effect of intraocular IL-10 on CNV was explored by administering IL-10 (100 ng) directly into the eye of IL-10-/- mice. This resulted in a significant increase in neovascularization that approached control levels (Figure 3B), with injection of IL-10 on day 3 being more effective than injection on day 0 (day of laser treatment). Thus, injection of IL-10, which prevents inflammatory cell recruitment to sites of inflammation [23,28], increased the level of CNV.
###end p 59
###begin p 60
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 242 246 242 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VMD2</italic>
###xml 263 268 263 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 281 291 281 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VMD2-IL-10</italic>
###xml 348 356 348 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g003">Figure 3</xref>
###xml 396 404 396 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g003">Figure 3</xref>
###xml 456 464 456 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g003">Figure 3</xref>
###xml 509 517 509 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g003">Figure 3</xref>
###xml 603 613 603 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VMD2-IL-10</italic>
###xml 752 757 752 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 831 840 831 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g002">Figures 2</xref>
###xml 845 846 845 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g003">3</xref>
###xml 146 149 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 188 193 <span type="species:ncbi:10090">mouse</span>
###xml 236 241 <span type="species:ncbi:9606">human</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
###xml 473 476 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 617 621 <span type="species:ncbi:10090">mice</span>
###xml 665 668 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 919 922 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Based on these findings, we hypothesized that high levels of IL-10 would prevent macrophage entry into the eye, resulting in increased pathologic CNV. To test this idea, we developed a Tg mouse overexpressing IL-10 in the RPE using the human VMD2 promoter. These IL-10 Tg mice (or VMD2-IL-10) expressed high levels of secreted IL-10 in the retina (Figure 3D) compared to transgene-negative mice (Figure 3C), but had completely normal retinal architecture (Figure 3E). When CNV was induced by laser treatment (Figure 3F), neovascularization was substantially elevated over that in controls. In addition, VMD2-IL-10 Tg mice did not show macrophage infiltrates in the CNV lesions (data not shown). Thus, direct injection of IL-10 and Tg overexpression of IL-10 both augmented new vessel formation. We conclude from these experiments (Figures 2 and 3) that inhibition of macrophage recruitment leads to increased levels of CNV.
###end p 60
###begin title 61
###xml 29 32 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Macrophages Directly Inhibit CNV
###end title 61
###begin p 62
###xml 129 137 129 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g004">Figure 4</xref>
###xml 168 169 168 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 286 287 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 298 299 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 312 313 312 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 374 375 374 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 427 435 427 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g004">Figure 4</xref>
###xml 458 459 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 479 480 479 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 673 674 673 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 49 52 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 233 236 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 422 425 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 594 597 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 721 724 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
We directly tested whether macrophages inhibited CNV by injecting cells into the vitreous cavity at the time of laser treatment. Figure 4A shows that injection of CD11b+ cells obtained from bone marrow cultures significantly reduced CNV. Inhibition was observed with injection of 1 x 105 and 5 x 105 cells. CD11b+ cells obtained from spleen by positive selection (>90% F4/80+; data not shown) also significantly inhibited CNV (Figure 4B), while splenic CD11c+ (dendritic) and CD3+ (T cells) were not effective. These data further support the idea that macrophages inhibit, rather than promote, CNV. The effect is attributable to macrophages and not dendritic cells as CD11c+ dendritic cells and T cells failed to inhibit CNV.
###end p 62
###begin title 63
###xml 20 23 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Macrophages Inhibit CNV via FasL-Mediated Cell Death
###end title 63
###begin p 64
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b017">17</xref>
###xml 620 621 620 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 633 636 633 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</italic>
###xml 655 658 655 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gld</italic>
###xml 769 777 769 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g005">Figure 5</xref>
###xml 794 795 794 795 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 827 832 827 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(gld)</italic>
###xml 884 885 884 885 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 987 990 987 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gld</italic>
###xml 1163 1166 1163 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gld</italic>
###xml 1235 1244 1235 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030310-sg002">Figure S2</xref>
###xml 689 693 <span type="species:ncbi:10090">mice</span>
###xml 849 852 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Inhibition of neovascularization by macrophages could be mediated by a direct effect of the cells on the developing vessels (via contact or through paracrine mechanisms), or it could be the result of a secondary effect of these cells on blood vessel formation through other resident or infiltrating cells. CD95/CD95L interactions are known to regulate vessel growth in the eye in the current model [17]. This regulation operates through the interaction of CD95L with the Fas antigen (CD95) on the choroidal blood vessels induced to grow by laser treatment. The CD95/CD95L pathway was examined by injecting purified CD11b+ cells from lpr (CD95-deficient), gld (CD95L-deficient), or wt (B6) mice into the vitreous to assess the effect on vessel formation. The results in Figure 5A show that CD11b+ cells lacking functional CD95L (gld) did not inhibit CNV. Thus, CD95L derived from CD11b+ cells is responsible for inhibiting new vessel formation. This effect is not due to the inability of gld macrophages to home to the laser lesion after injection since there was no difference in the number of carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled wt or gld macrophages per lesion when they were examined 3 d after injection (Figure S2).
###end p 64
###begin p 65
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b030">30</xref>
###xml 300 301 300 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 433 434 433 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 456 464 456 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g005">Figure 5</xref>
###xml 534 535 534 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 616 624 616 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030310-g005">Figure 5</xref>
Macrophages are known to both promote and inhibit inflammatory responses, but they are not typically FasL+ unless stimulated [30]. This suggests that activation (or at least interaction) with the damaged retinal tissue might promote CD95L expression, leading to acquisition of killing function. CD11b+ cells purified from spleen were subjected to necrotic cells (from the retina) or LPS and then tested for their ability to kill CD95+ targets. As shown in Figure 5B, cells fed necrotic cells or treated with LPS were able to kill CD95+ targets. This was through upregulation of CD95L on macrophages by both stimuli (Figure 5C).
###end p 65
###begin title 66
Discussion
###end title 66
###begin p 67
###xml 73 76 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 351 354 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Our data show that macrophages are protective against the development of CNV in the eye and that IL-10 regulates macrophage function. This finding suggests that in AMD a functioning immune system is important in preventing blindness from this disease. Since current treatments limit vision loss but are not specifically designed to prevent or reverse CNV, our results also suggest a novel approach to the design of therapies.
###end p 67
###begin p 68
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b031">31</xref>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b032">32</xref>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b014">14</xref>
###xml 701 704 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 749 752 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Inflammation, specifically macrophage infiltration, is known to promote a number of pathologic processes including cancer, heart disease, and eye disorders. The ability of these cells to produce a variety of molecules that stimulate blood vessel growth is thought to be an important component in disease progression. However, macrophage function is highly complex as these cells can also promote wound healing [31,32] and control vessel growth during developmental processes [14]. Our results demonstrate a potentially new role for macrophages in blinding eye disorders, where macrophages may not be proangiogenic but function to limit the spread of choroidal blood vessels in the eye. This effect on CNV has implications for neovascular AMD, where CNV is the major pathogenic factor.
###end p 68
###begin p 69
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b033">33</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b033">33</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b034">34</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b035">35</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b036">36</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b016">16</xref>
###xml 71 77 <span type="species:ncbi:9606">people</span>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
###xml 314 322 <span type="species:ncbi:9606">Patients</span>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
###xml 657 660 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Advanced AMD that leads to severe visual loss affects almost 2 million people in the United States [33]. By 2020, the number of patients with all stages of AMD in the industrialized world is expected to increase by about 50%. AMD now accounts for over 40% of blindness among the institutionalized elderly [33,34]. Patients with advanced AMD rate their quality of life lower than patients with AIDS and dialysis-dependent renal failure [35,36]. Current treatments are designed to limit further visual loss, but these are only marginally effective [16]. There is no treatment that can reverse the damage to vision. Consequently, insights into the etiology of CNV associated with AMD, as described in this report, add significantly to the information needed to design effective treatments.
###end p 69
###begin p 70
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b004">4</xref>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b005">5</xref>
###xml 703 712 703 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0030310-sg003">Figure S3</xref>
###xml 818 820 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b037">37</xref>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b038">38</xref>
###xml 494 497 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 546 549 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
While it is clear that the immune system can play a role in neovascularization, there has been conflicting evidence regarding the role of the immune system in neovascular AMD. The most popular idea is that macrophages (and inflammation) are proangiogenic. Studies suggesting this used the laser model described here and systemically depleted phagocytic cells by injection of the compound clodronate encapsulated in liposomes [4,5]. Since systemic depletion of phagocytes decreased the level of CNV, the authors concluded that macrophages promote CNV. When we examined this system, we found that liposomes can actually enter developing endothelial cells found in the laser-induced neovascular complexes (Figure S3). These findings, coupled with the fact that liposomes are known to enter a wide variety of other cells [37,38], suggest that the effects observed may be due to the toxicity of the clodronate liposomes directly on sprouting endothelial cells.
###end p 70
###begin p 71
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b013">13</xref>
###xml 1042 1044 1042 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b039">39</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b041">41</xref>
###xml 1427 1429 1427 1429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b042">42</xref>
###xml 1534 1536 1534 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b014">14</xref>
###xml 1553 1554 1553 1554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b002">2</xref>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 170 173 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 345 348 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 446 449 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 509 512 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 735 741 <span type="species:ncbi:9606">humans</span>
###xml 888 891 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1248 1251 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1336 1339 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1351 1359 <span type="species:ncbi:9606">patients</span>
A recent study suggested that macrophages may be anti-angiogenic. These authors demonstrated that mice lacking a macrophage recruitment chemokine (ccl-2) had spontaneous CNV [13]. Although these authors did not discuss the possibility, this observation suggests that the inability to recruit macrophages into the eye leads to the development of CNV. Not only do our results support this idea, but we have directly tested it in the laser model of CNV. Our study shows that increased macrophage influx inhibits CNV, while treatments that prevent macrophage entry into the eye suppress the anti-angiogenic response of macrophages. Data from our study complement the natural history of AMD and the etiology of inflammatory eye diseases in humans. Although leukocytes including macrophages, lymphocytes, erythrocytes, and other cells of hematopoietic origin have been isolated from samples of CNV and identified by immunohistochemistry or electron microscopy, there is no conclusive evidence about whether these cells are pro- or anti-angiogenic [39-41]. The possibility remains that these cells represent an epiphenomenon related to the growth of abnormal blood vessels in the subretinal space. Our data demonstrate a novel role for macrophages in the CNV lesions that is of potential therapeutic relevance. Clinical observations show that CNV in uveitis patients, who have significant inflammation in the eye, is less aggressive [42]. Our findings also complement recent evidence that macrophages are anti-angiogenic during development [14] and in tumors [2]. Based on this information and the data presented in this report we conclude that inflammation may be protective.
###end p 71
###begin p 72
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b009">9</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b011">11</xref>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b012">12</xref>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b043">43</xref>
###xml 783 786 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Recent genetic-linkage-based evidence suggests the potential importance of complement factor H in AMD [9,11,12]. However, the lack of functional data leaves these important observations still open to interpretation, as they are also consistent with the idea that a healthy immune system (e.g., complement pathway) may actually protect against blindness. We would suggest that one explanation for the linkage between complement factor H and AMD might be that polymorphisms that lead to increased AMD are associated with reduced macrophage recruitment to the chorio-retinal tissues. The elderly, who are at risk for the development of AMD, are known to have compromised immune function [43]. Thus, a disabled macrophage response may be an additional risk factor for the development of CNV and blindness. We would further suggest that physiologic immune surveillance and normal macrophage function are critical in controlling pathologic neovascularization.
###end p 72
###begin p 73
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b023">23</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b028">28</xref>
The pivotal role for IL-10 in this model is likely related to the anti-inflammatory properties of the cytokine and its ability to inhibit cytokines that attract macrophages [23,28]. We can find no effect of IL-10 on endothelial cells (data not shown). Increases in chemotactic cytokines would be predicted when IL-10 is not present, and one would expect that the loss of cytokines that promote infiltration of monocytes or macrophages would predispose to AMD.
###end p 73
###begin p 74
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b017">17</xref>
###xml 487 489 487 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b017">17</xref>
###xml 643 644 643 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 773 774 773 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 934 935 934 935 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 974 975 974 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 66 69 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 168 171 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 178 182 <span type="species:ncbi:10090">mice</span>
###xml 257 260 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 482 485 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 618 621 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 714 717 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1080 1083 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Our studies also demonstrate that macrophages use FasL to inhibit CNV. We have demonstrated previously that FasL expressed on RPE cells is important for the control of CNV [17]: mice defective in the expression of FasL on RPE cells had massive increases in CNV. We believe that our current observations complement this finding, since we believe that FasL on both RPE cells and macrophages is necessary. The loss of FasL on RPE cells leads to substantial (5- to 8-fold) increases in CNV [17], and we would not expect the few macrophages that enter the lesion (10-20 per lesion) to be able to control this high level of CNV even if they are FasL+. When FasL is present on the RPE, as occurs in most experiments, the CNV is more modest and then amenable to control by the FasL+ macrophages that infiltrate the lesions. It should be noted that the role of macrophage-expressed FasL was revealed only when we injected large numbers of FasL+ macrophage into the vitreous (1-5 x 105). Therefore, we conclude that RPE-derived FasL and macrophage-derived FasL are important in controlling CNV.
###end p 74
###begin p 75
###xml 586 594 <span type="species:ncbi:9606">patients</span>
###xml 612 615 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 759 767 <span type="species:ncbi:9606">patients</span>
###xml 817 820 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1272 1280 <span type="species:ncbi:9606">patients</span>
Our data suggest potential sites for therapeutic intervention in AMD. Since the absence of IL-10 results in increased macrophage influx and reduced neovascularization, novel targeting therapies designed to inhibit local IL-10 function, promote tissue-specific macrophage activity, and/or target the CD95/CD95L pathway should be considered as treatments for neovascular AMD. IL-10 activity in the eye can be inhibited by local administration of neutralizing antibodies, inhibitory RNA, or aptamers. Although the most immediate application for this form of therapy would presumably be in patients with preexisting CNV in order to limit or reverse vision loss, long-term inhibition of IL-10 function in the eye could potentially be used as preventive therapy in patients with dry AMD who are at high risk for developing CNV. In addition to demonstrating that IL-10 is an attractive therapeutic target in AMD, we have also shown that the role of macrophages in angiogenesis might be more complex than previously suggested. The anti-angiogenic functions of macrophages should be considered in evaluating any therapies that might nonselectively neutralize all macrophage effector function because of the potentially devastating consequences on the disease process and vision in patients with AMD.
###end p 75
###begin title 76
Supporting Information
###end title 76
###begin title 77
Source of IL-10
###end title 77
###begin p 78
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 67 70 67 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 185 186 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 256 257 250 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 310 315 304 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 315 318 309 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 353 354 344 345 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 388 393 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 393 396 384 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 426 427 414 415 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 205 208 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 276 280 <span type="species:ncbi:10090">mice</span>
###xml 373 376 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 397 401 <span type="species:ncbi:10090">mice</span>
Bone marrow chimeras were generated to test the source IL-10. IL-10-/- mice that were reconstituted with B6 bone marrow (BM) (volume of the neovascular complex: 10,143.9 +/- 1,962.8 mum3) showed levels of CNV comparable to B6 mice (12,756.7 +/- 3,744.4 mum3). In contrast, B6 mice that were reconstituted with IL-10-/- bone marrow (3,292.7 +/- 632.9 mum3) showed levels of CNV similar to IL-10-/- mice (3,758.7 +/- 1,259.3 mum3). This finding demonstrates the source of IL-10 is hematopoietic cells. Asterisks indicate values significantly different from control.
###end p 78
###begin p 79
(445 KB TIF)
###end p 79
###begin p 80
Click here for additional data file.
###end p 80
###begin title 81
###xml 38 41 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Homing of CFSE-Labeled Macrophages to CNV Lesions
###end title 81
###begin p 82
###xml 29 32 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gld</italic>
###xml 243 246 243 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gld</italic>
###xml 296 297 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 33 37 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
Macrophages from B6-wt or B6-gld mice were labeled with CFSE and injected into the vitreous cavity on the day of laser treatment. The number of macrophages per laser lesion were counted on day 3 and were not significantly different for B6 and gld mice (9.5 +/- 1.4 and 7.6 +/- 2.0, respectively; p = 0.24).
###end p 82
###begin p 83
(593 KB TIF)
###end p 83
###begin p 84
Click here for additional data file.
###end p 84
###begin title 85
###xml 47 50 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Green-Fluorescent-Protein-Labeled Liposomes in CNV Lesions
###end title 85
###begin p 86
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Green-fluorescent-protein-labeled liposomes were injected intravenously into B6-wt mice on the day of laser treatment. The presence of liposomes in the developing blood vessels within the laser lesions was analyzed on day 3. Shown is a representative lesion that demonstrates detectable liposomes in the laser lesion.
###end p 86
###begin p 87
(234 KB TIF)
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin title 89
Additional Methods
###end title 89
###begin p 90
(60 KB DOC)
###end p 90
###begin p 91
Click here for additional data file.
###end p 91
###begin title 92
Accession Numbers
###end title 92
###begin p 93
###xml 93 96 93 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fas</italic>
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FasL</italic>
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 35 40 <span type="species:ncbi:10090">mouse</span>
The NCBI accession numbers for the mouse genes and gene products discussed in this paper are Fas gene (NM_007987), Fas protein (NP_032013), FasL gene (NM_010177), FasL protein (AAB33780), IL-10 gene (NC_000067), and IL-10 protein (NP_034678).
###end p 93
###begin title 94

###end title 94
###begin p 95
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author Contributions.</bold>
Author Contributions. RSA and TAF designed the study. RSA, JR, and TAF analyzed the data. RSA, JH, and TAF contributed to writing the paper.
###end p 95
###begin p 96
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: This study was supported by National Institutes of Health (NIH) grant K08EY016139 (RSA), Diabetes Research and Training Center grant NIH 5 P60 DK20579 (RSA), a Carl Marshall Reeves and Mildred Almen Reeves Foundation Award (RSA), a Research to Prevent Blindness Career Development Award (RSA), an American Federation for Aging Research grant (RSA), NIH grants EY12826 (TAF) and EY06765 (TAF), and the Washington University Department of Ophthalmology and Visual Sciences core grant (EY08972). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 96
###begin p 97
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 97
###begin title 98
Abbreviations
###end title 98
###begin p 99
age-related macular degeneration
###end p 99
###begin p 100
C57/BL6
###end p 100
###begin p 101
carboxyfluorescein diacetate succinimidyl ester
###end p 101
###begin p 102
choroidal neovascularization
###end p 102
###begin p 103
Fas ligand
###end p 103
###begin p 104
lipopolysaccharide
###end p 104
###begin p 105
retinal pigment epithelium
###end p 105
###begin p 106
transgenic
###end p 106
###begin p 107
wild-type
###end p 107
###begin title 108
References
###end title 108
###begin article-title 109
Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1beta-induced neovascularization and tumor growth
###end article-title 109
###begin article-title 110
Macrophage receptors and immune recognition
###end article-title 110
###begin article-title 111
Inflammation, atherosclerosis, and coronary artery disease
###end article-title 111
###begin article-title 112
Macrophage depletion inhibits experimental choroidal neovascularization
###end article-title 112
###begin article-title 113
Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization
###end article-title 113
###begin article-title 114
Epidemiology of age-related maculopathy: A review
###end article-title 114
###begin article-title 115
The epidemiology of age-related macular degeneration
###end article-title 115
###begin article-title 116
Alzheimer disease in the US population: Prevalence estimates using the 2000 census
###end article-title 116
###begin article-title 117
Complement factor H polymorphism and age-related macular degeneration
###end article-title 117
###begin article-title 118
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration
###end article-title 118
###begin article-title 119
Complement factor H variant increases the risk of age-related macular degeneration
###end article-title 119
###begin article-title 120
Complement factor H polymorphism in age-related macular degeneration
###end article-title 120
###begin article-title 121
###xml 91 95 <span type="species:ncbi:10090">mice</span>
An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice
###end article-title 121
###begin article-title 122
WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature
###end article-title 122
###begin article-title 123
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-TAP Report 2
###end article-title 123
###begin article-title 124
Pegaptanib for neovascular age-related macular degeneration
###end article-title 124
###begin article-title 125
Fas ligand (CD95 ligand) controls angiogenesis beneath the retina
###end article-title 125
###begin article-title 126
Stimulation of neovascularization by the anti-angiogenic factor PEDF
###end article-title 126
###begin article-title 127
Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin
###end article-title 127
###begin article-title 128
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate
###end article-title 128
###begin article-title 129
AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization
###end article-title 129
###begin article-title 130
Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: Results of a phase I clinical trial
###end article-title 130
###begin article-title 131
Regulation of contact hypersensitivity by interleukin 10
###end article-title 131
###begin article-title 132
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
###end article-title 132
###begin article-title 133
Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium
###end article-title 133
###begin article-title 134
A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis
###end article-title 134
###begin article-title 135
Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes
###end article-title 135
###begin article-title 136
Interleukin-10 and the interleukin-10 receptor
###end article-title 136
###begin article-title 137
###xml 40 43 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis
###end article-title 137
###begin article-title 138
Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes
###end article-title 138
###begin article-title 139
Wound healing: An overview of acute, fibrotic and delayed healing
###end article-title 139
###begin article-title 140
Understanding the role of immune regulation in wound healing
###end article-title 140
###begin article-title 141
Prevalence of age-related macular degeneration in the United States
###end article-title 141
###begin article-title 142
Visual impairment and eye diseases in elderly institutionalized Australians
###end article-title 142
###begin article-title 143
The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom
###end article-title 143
###begin article-title 144
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration
###end article-title 144
###begin article-title 145
###xml 51 56 <span type="species:ncbi:9606">human</span>
Interactions of PC/Chol and PS/Chol liposomes with human cells in vitro
###end article-title 145
###begin article-title 146
Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels
###end article-title 146
###begin article-title 147
Immunological and aetiological aspects of macular degeneration
###end article-title 147
###begin article-title 148
Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: Submacular surgery trials report no. 7
###end article-title 148
###begin article-title 149
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Clinicopathologic studies of eyes that were obtained postmortem from four patients who were enrolled in the submacular surgery trials: SST report no. 16
###end article-title 149
###begin article-title 150
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Ocular neovascularization in patients with uveitis
###end article-title 150
###begin article-title 151
The aging innate immune system
###end article-title 151
###begin title 152
Figures and Tables
###end title 152
###begin title 153
###xml 30 33 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
IL-10 and Neovascularization (CNV)
###end title 153
###begin p 154
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 34 37 34 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 93 94 90 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 104 109 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 109 112 106 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 137 138 131 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 229 230 220 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 290 291 278 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 362 364 350 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
###xml 415 416 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 446 448 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b017">17</xref>
###xml 449 451 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030310-b018">18</xref>
###xml 10 13 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
(A and B) CNV was induced in IL-10-/- (volume of the neovascular complex: 829.6 +/- 225.7 mum3) and B6 (IL-10+/+; 8,830.7 +/- 1,130.3 mum3) mice (A) and B6 mice injected on days 0, 3, and 5 with anti-IL-10 (10,115.3 +/- 850.5 mum3) or isotype control antibody (IgG2b; 33,602.3 +/- 317.4 mum3) (B). Asterisks indicate values significantly different from control; p-values given in parentheses are based on Student's t test performed as described [17,18].
###end p 154
###begin p 155
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 193 196 193 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 161 164 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
(C and D) Seven days following laser treatment, the volumes of the neovascular complexes (green) were determined by confocal microscopy. Shown is representative CNV in a B6 eye (C) and an IL-10-/- eye (D).
###end p 155
###begin title 156
###xml 24 27 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Cellular Infiltrates in CNV Lesions
###end title 156
###begin p 157
###xml 194 199 194 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 199 202 199 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
(A-C) On day 7 following laser treatment, whole mount stains were performed to determine the cells present in the area of the neovascular complex. Stains for CD11b were performed on (A) B6, (B) IL-10-/-, and (C) B6 mice treated with neutralizing anti-IL-10. Images were take by confocal microscopy (magnification 200x) centered on the laser lesion.
###end p 157
###begin p 158
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 125 129 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL10</italic>
###xml 129 132 127 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
(D) The number of CD11b+ cells per lesion was counted (200x high-power field centered on the laser lesion) (B6, 6.3 +/- 0.9; IL10-/-, 22.6 +/- 2.1; B6 + anti-IL10, 22.5 +/- 2.5). Asterisks indicate values significantly different from control.
###end p 158
###begin p 159
(E) Dual staining was performed on day 7 following laser treatment using FITC-conjugated anti-CD11b (green) and PE-conjugated anti-F4/80 (red) (magnification 400x).
###end p 159
###begin title 160
###xml 47 50 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Inhibition of Macrophage Infiltration Promotes CNV
###end title 160
###begin p 161
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 9 12 9 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 108 109 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 147 148 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 188 189 179 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 214 217 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
(A) IL-10-/- mice were injected with anti-CD11b (volume of the neovascular complex: 12,903.1 +/- 2,171.3 mum3), anti-F4/80 (9,977.3 +/- 1,572.7 mum3), or control IgG (2,262.3 +/- 313.4 mum3) on days -1, 0, and +1. CNV volumes were determined on day 7.
###end p 161
###begin p 162
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-10</italic>
###xml 9 12 9 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 77 78 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 93 99 90 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rIL-10</italic>
###xml 161 162 155 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 197 198 188 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
(B) IL-10-/- mice were injected in the vitreous with PBS (1,394 +/- 382.4 mum3) or 100 ng of rIL-10 on day 0 (the day of laser treatment; 4,033.6 +/- 1,026.5 mum3) or day 3 (6,949.8 +/- 1,475.5 mum3).
###end p 162
###begin p 163
###xml 74 84 74 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VMD2-IL-10</italic>
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
(C and D) Cross-sections of the retinas of a control littermate (C) and a VMD2-IL-10 Tg mouse (D) stained with anti-IL-10 and examined by confocal microscopy.
###end p 163
###begin p 164
###xml 54 64 54 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VMD2-IL-10</italic>
###xml 68 73 <span type="species:ncbi:10090">mouse</span>
(E) Hematoxylin and eosin staining of the retina of a VMD2-IL-10 Tg mouse (magnification 200x).
###end p 164
###begin p 165
###xml 4 14 4 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VMD2-IL-10</italic>
###xml 48 49 45 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 99 100 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 140 143 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
(F) VMD2-IL-10 Tg mice (24,428.6 +/- 4,360.7 mum3) and littermate controls (6,830.1 +/- 1,324.9 mum3) were subjected to laser treatment and CNV volumes were determined on day 7.
###end p 165
###begin p 166
###xml 64 66 64 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
Asterisks indicate values significantly different from control; p-values are given in parentheses.
###end p 166
###begin title 167
###xml 34 37 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Injection of Macrophages Inhibits CNV
###end title 167
###begin p 168
###xml 324 326 324 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p-</italic>
###xml 377 378 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Cells obtained from bone marrow (BM) cultures (A) or spleen (B) were purified by magnetic beads and injected into the vitreous cavity on the day of laser treatment. Seven days later, the volume of the neovascular complex was determined by confocal microscopy. Asterisks indicate values significantly different from control; p-values given in parentheses are based on Student's t test.
###end p 168
###begin p 169
###xml 84 85 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 106 107 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 136 137 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 162 163 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 192 193 183 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
(A) Volume of the neovascular complex for injection of PBS (14,470.9 +/- 1,636.4 mum3), CD11b cells-1 x 105 cells (2,431.2 +/- 551.3 mum3), and CD11b cells-5 x 105 cells (5,274.2 +/- 772.5 mum3).
###end p 169
###begin p 170
###xml 84 85 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 123 124 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 161 162 152 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 206 207 194 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
(B) Volume of the neovascular complex for injection of PBS (12,857.9 +/- 1,094.9 mum3), CD3 cells (14,960.5 +/- 2,502.0 mum3), CD11b cells (4,135.1 +/- 714.4 mum3), and CD11c cells (15,063.3 +/- 1,982.4 mum3).
###end p 170
###begin title 171
###xml 20 23 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Macrophages Inhibit CNV via CD95L
###end title 171
###begin p 172
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr,</italic>
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gld</italic>
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 299 300 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 328 329 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 332 335 326 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gld</italic>
###xml 361 362 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 369 372 360 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</italic>
###xml 395 396 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 167 170 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
(A) CD11b+ cells from B6, B6-lpr, and B6-gld mice were purified from spleen, and 1 x 105 cells were injected into the vitreous cavity on the day of laser induction of CNV. Seven days later, the volume of the neovascular complex was determined by confocal microscopy for PBS (11,786.4 +/- 1,907.3 mum3), B6 (2,084.6 +/- 874.8 mum3), gld (15,824.9 +/- 1,483.6 mum3), and lpr (5,443.9 +/- 542.1 mum3). Asterisks indicate values significantly different from control.
###end p 172
###begin p 173
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
(B) Purified CD11b+ cells were cultured overnight with LPS or necrotic retina and tested for killing against L1210-Fas.
###end p 173
###begin p 174
(C) The expression of CD95L in CD11b cells was determined by flow cytometry following overnight culture with LPS (dotted line) or necrotic retina (solid line). The line with shading underneath represents untreated cells.
###end p 174

